Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The landscape of cancer treatment has been dramatically reshaped by the advent of targeted therapies, moving away from broad-spectrum chemotherapy towards drugs that precisely inhibit cancer-driving molecular pathways. Lorlatinib stands as a prime example of this evolution, representing a sophisticated third-generation tyrosine kinase inhibitor (TKI) specifically developed for ALK-positive non-small cell lung cancer (NSCLC).
At its core, lorlatinib functions by inhibiting the aberrant activity of the Anaplastic Lymphoma Kinase (ALK) protein. In ALK-positive NSCLC, the ALK gene undergoes a rearrangement, leading to the production of a fusion protein that continuously signals cancer cells to grow and divide uncontrollably. Lorlatinib is designed to bind to the ATP-binding pocket of this abnormal ALK protein, effectively blocking these growth signals. What sets lorlatinib apart is its ability to inhibit a wide array of ALK resistance mutations that often emerge after treatment with earlier TKIs, such as crizotinib, ceritinib, and alectinib. This broad-spectrum activity makes it a crucial option for patients who have experienced disease progression on prior therapies.
Furthermore, lorlatinib's unique chemical structure allows it to effectively penetrate the blood-brain barrier. This is a significant clinical advantage, as a substantial proportion of patients with ALK-positive NSCLC develop brain metastases. By targeting cancer cells within the central nervous system, lorlatinib can help prevent or slow the progression of these metastases, thereby improving patient outcomes and quality of life. The scientific rationale behind lorlatinib's design highlights a continuous effort to develop more effective and durable treatments for complex cancers like NSCLC.
The journey from understanding cancer genetics to developing precision medicines like lorlatinib showcases the power of pharmaceutical research. NINGBO INNO PHARMCHEM CO.,LTD. plays a vital role in this ecosystem by supplying high-purity active pharmaceutical ingredients, enabling researchers and manufacturers to bring these advanced therapies to patients. The ongoing buy of lorlatinib at competitive prices ensures accessibility for the development of innovative cancer treatments.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
